Aptamers Sgc8 In The Diagnostic Studies Of Acute Leukemia

Acute leukemia is a type of malignant disease that originates from the hematopoietic system,which is mainly diagnosed through multi-disciplinary examinations.One of them is flow cytometry using monoclonal antibodies to perform immunophenotyping and minimal residual disease monitoring for acute leukemia,which has been one of the most important diagnostic methods clinically.However,due to the heterogeneity of tumor cells and possiblely the drift of antigen phenomenon,it is sometimes impossible to follow up the tumor cells with the originally used markers.Furthermore,the antibodies against the new markers need to undergo a longer period from development to clinical application.Nucleic acid aptamer is a kind of artificially screened oligonucleotide chain,which has similar specificity and affinity to antibody.It is easy to produce,synthesize and modify.Its screening technology represents a revolutionary progress,that is,it can quickly develop against New ligands for the target.sgc8 was selected from the acute leukemia tumor cell line CEM cells,and its target PTK7 protein is expressed in a variety of malignant tumors,so sgc8 has been reported to be used in a number of tumor studies.In this study,in order to study the diagnostic ability of aptamers in acute leukemia,the aptamer sgc8 was used to detect bone marrow samples with various types of acute leukemia and normal samples,which aims to study the recognition ability of sgc8 to the different cell populations,and explore its application value in the diagnosis of acute leukemia.In this study,a method were established to directly detect the bone marrow samples by using aptamers in vitro.Via this method,the aptamer sgc8 was used to detect a total of 83 different bone marrow samples,in order to explore the ability of sgc8 to recognize various cell populations.In T-ALL and AML samples,the sgc8 can specifically recognize tumor cells while there is no significant recognition effect in B-ALL samples.The recognition ability is different between various AML subtypes,but no difference in T-ALL subtypes.In healthy bone marrow samples,sgc8 can specifically recognize the blast cells without identifing early B cells and other mature cell populations.In addition,compared with most common-used antibodies,sgc8 has a higher recognition positive rate for AML and T-ALL tumor cells.In conclusion,the aptamer sgc8 has specific recognition ability in AML,T-ALL and healthy bone marrow samples,but no significant recognition in B-ALL samples.sgc8 has a higher recognition positive rate than most common-uesed antibodies.These suggest that sgc8 can be considered as an auxiliary diagnostic tool for acute leukemia.